drugset / Trial / NCT06498479
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).
Timeline
- Start
- 2024-07-04
- Primary completion
- 2026-09-30
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-20093 | Other / unclassified | 8 mg/kg | Intravenous |
| Comparator | Topotecan | Small molecule | — | — |